Skip to content
Screener

Wave Life Sciences WVE Financing Cash Flow

Financing Cash Flow at other companies

Eli Lilly logo
Eli LillyLLY
$8.43B+777%
Sarepta Therapeutics, Inc. logo
Sarepta Therapeutics, Inc.SRPT
$241K-98.1%
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
-$412.29M-33,163%
Madrigal Pharmaceuticals, Inc. logo
Madrigal Pharmaceuticals, Inc.MDGL
$3.11M+78.7%
ALN
Alnylam PharmaceuticalsALNY
$36.24M-32.6%
Beam Therapeutics logo
Beam TherapeuticsBEAM
$96.61M-79.6%

Other financials

Income statement

See full
Revenue$2.3M-73.9%
Operating income-$73.8M-39.9%
Net income-$69.4M-37.4%
EPS (diluted)-$0.34-9.7%

Balance sheet

See full
Cash & equivalents$368.0M+76.5%
Total debt$43.6M+101%
Total equity$453.5M+226%
Total assets$558.3M+121%

Cash flow

See full
Operating cash flow-$53.6M-16.5%
CapEx$884.0K+189%
Free cash flow-$54.5M-17.6%

Valuation

See full
Market cap$1.2B-7.3%
Enterprise value$877.58M-21.0%
P/S20.6×-16.6×

Profitability

See full
Operating margin-75.7%-33.6pp
Net margin-66.5%-29.9pp
FCF margin-27.2%-12.6pp

Returns & leverage

See full
Return on equity-68.3%
Debt / equity0.1×-0.1×
Current ratio10×+7.4×

Where this comes from

Reported directly by Wave Life Sciences in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The source filing: Wave Life Sciences’s 10-Q, filed July 30, 2026.

Filed
Jul 30, 2026, 7:50 AM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001193125-26-324949
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Proceeds from issuance of ordinary shares pursuant to the “at-the-market” equity program, net of offering costs12,361
Proceeds from the exercise of share options2,2643,045
Proceeds from the ESPP593442
Net cash provided by financing activities2,85715,848
Effect of foreign exchange rates on cash, cash equivalents, and restricted cash119101
Net decrease in cash, cash equivalents, and restricted cash(234,051)(93,573)
Cash, cash equivalents, and restricted cash, beginning of period605,874305,838
Cash, cash equivalents, and restricted cash, end of period$371,823$212,265

Item 1. Financial Statements

FAQ

What is Wave Life Sciences's financing cash flow?
Wave Life Sciences (WVE) reported financing cash flow of $330K in Q2 2026.
How has Wave Life Sciences's financing cash flow changed year-over-year?
Wave Life Sciences's financing cash flow decreased by 97.2% year-over-year, from $11.69M to $330K.
What is the long-term trend for Wave Life Sciences's financing cash flow?
Over 4 years (2021 to 2025), Wave Life Sciences's financing cash flow has grown at a 72.0% compound annual growth rate (CAGR), from $55.83M to $488.24M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

Ask your AI about Wave Life Sciences's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude